Compare Byrna Technologies Inc (BYRN) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Byrna Technologies Inc vs Smith & Nephew plc — how do they compare? Byrna Technologies Inc trades at $4.31 (market cap $106.74M), while Smith & Nephew plc trades at $29.79 (market cap $12.54B). The key difference: Smith & Nephew plc is far larger — about 117.5× Byrna Technologies Inc's market cap, and Smith & Nephew plc pays a 2.65% dividend while Byrna Technologies Inc pays none. Which is the better fit depends on your goals.
| BYRN | SNN | |
|---|---|---|
Market Cap | $106.74M | $12.54B |
Sector | Technology | Health |
52-Week High | $27.63 | $38.70 |
52-Week Low | $3.18 | $28.73 |
Enterprise Value | $98.35M | $15.57B |
Dividend Yield | — | 2.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BYRN trades at $4.34, down 10.52% in 24 hours, with a mixed technical outlook showing bullish moving averages but neutral oscillators. The company reported a net loss in 2026 with a negative net income margin of -3.39%, though it maintains a strong gross profit margin of 52.51%. Recent leadership appointments aim to bolster marketing and retail expansion, while Q2 2026 earnings missed estimates with a loss of $0.44 per share.
The outlook is challenged by recent earnings misses and declining revenue, but analyst consensus remains bullish with 71% buy ratings. Key risks include execution in sales turnaround and competitive pressures. Upside depends on successful implementation of new growth initiatives and improved financial performance in upcoming quarters.
Smith & Nephew (SNN) trades at $29.76, down 1.06% with bearish technical signals. The company shows improving fundamentals with revenue growth from $5.8B to $6.2B and net income margin expanding to 10.08% in 2025. Recent Q2 2026 earnings beat expectations but the company lowered full-year revenue guidance from 6% to 4% growth due to U.S. Orthopaedics weakness.
While valuation multiples appear reasonable (P/E 20.41, EV/EBITDA 9.9), the stock faces headwinds from mixed earnings performance and cautious analyst sentiment. The primary investment case hinges on execution in robotics and wound care segments offsetting orthopedic challenges, with downside risk from continued U.S. market softness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Byrna Technologies Inc
Byrna Technologies specializes in less-lethal personal security devices. It develops and manufactures innovative handheld launchers and projectiles designed for self-defense, law enforcement, and private security use.
Read more on BYRN →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
